替雷利珠单抗疑致大疱性表皮松解症  

Epidermolysis Bullosa Induced by Tislelizumab

作　　者：刘宏尉 杨嘉永[1] 颜志文[1] LIU Hong-wei;YANG Jia-yong;YAN Zhi-wen(Department of Pharmacy,The First Affliated Hospital of Xiamen University,Xiamen 361000,China)

机构地区：[1]厦门大学附属第一医院药剂科,福建厦门361000

出　　处：《海峡药学》2022年第6期149-151,共3页Strait Pharmaceutical Journal

摘　　要：1例因肺癌使用替雷利珠单抗200 mg免疫治疗的患者,行第三周期治疗后全身出现斑片状皮疹,呈进行性加重。躯干、四肢可见片状红斑、水疱、大疱,水疱呈松弛状,疱液澄清,部分疱壁剥脱形成浅糜烂面,瘙痒明显,伴触痛,诊断为大疱性表皮松解症,考虑很可能是替雷利珠单抗引起,予静滴甲泼尼龙,口服依巴斯汀、酮替芬、莫西沙星,外用炉甘石洗剂、重组人表皮生长因子、离子抗菌敷料,水疱予抽液处理,10 d后明显好转,甲泼尼龙予剂量减半,17 d后患者皮肤干燥无渗出,皮损痊愈,恢复良好。One patient was treated with immunotherapy using Tislelizumab(200 mg)owing to the occurrence of lung cancer.After the third cycle of treatment,the patient developed systemic patchy rash,which was gradually aggravated.Flaky erythema,blisters and bullae could be found on the trunk and limbs of the patient.The blisters were loose in distribution,with clear blister fluid,and superficial erosive surface formed owing to the exfoliation of the part of the blister wall,showing obvious itching symptom and accompanied by tenderness.The patient was diagnosed with epidermolysis bullosa,which was considered to be induced by the use of Tislelizumab.Accordingly,the patient was treated by intravenous infusion of methylprednisolone,oral administration of ebastine,ketotifen and moxifloxacin,external application of calamine lotion,recombinant human epidermal growth factor and ion antibacterial dressing.Besides,the blisters were treated by aspiration.The patient showed obvious improvement after 10 d of treatment,and the dosage of methylprednisolone was reduced by half.After 17 d of treatment,the patient recovered well,showing dry skin without exudation and cured skin lesion.

关 键 词：替雷利珠单抗 表皮松解 大疱性 

分 类 号：R969.4[医药卫生—药理学]